Joseph Cherabie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joseph Cherabie has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Aditi Ramakrishnan
Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO
1 shared publication- Adriana M. Rauseo
Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, USA
1 shared publication Ami Multani
Fenway Health , Boston, Massachusetts
1 shared publication- Andrej Spec
Division of Infectious Diseases, Department of Medicine, Washington University in St Louis School of Medicine , St Louis, Missouri
1 shared publication Andrew Brand
Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO
1 shared publication- Aniruddha Hazra
Section of Infectious Diseases and Global Health, University of Chicago , Chicago, Illinois
1 shared publication
Latest Publications
- 22 August 2026
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 53 (11) , 814-817
LIMIT Trial: Lidocaine With Intramuscular Injection of Benzathine Penicillin G for Treponema pallidum Treatment
Background: Studies have shown that intramuscular benzathine penicillin G (BPG) or bicillin injections cause severe pain in many patients, which may reduce adherence. Local anesthetics mixed with BPG may reduce injection pain without affecting drug effectiveness. The objective of this study was to examine if there is any benefit of adding 0.5 mL 1% lidocaine to prepackaged BPG, with respect to pain, compared with standard of care, in the treatment of Treponema pallidum infections, both 10 min and 24 h after injection. Methods: This study is a double-blinded randomized placebo-controlled trial of the effect on pain of the addition of 0.5 mL 1% lidocaine solution to a prepackaged BPG injection, compared with the addition of 0.5 mL normal saline solution, in adults being treated for syphilis ( T. pallidum ) infections, within the Infectious Diseases Clinic at Washington University in St. Louis, MO. Results: Preliminary analysis included 15 participants. A Wilcoxon signed-rank test indicated a statistically significant reduction in pain 10 min after lidocaine injection compared with the saline injection ( z = −2.65, P = 0.008). The mean pain score following administration, after 10 min, of the lidocaine solution was 3, compared with 6.73 for the saline solution. Overall, 87% of participants reported at least a 2-point reduction in pain scores after 10 min with lidocaine relative to saline. However, no significant difference in pain scores was observed between the 2 solutions at the 24-h follow-up. Conclusion: This trial demonstrates that lidocaine can help reduce the pain associated with intramuscular injections of BPG.
- 22 August 2026
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 53 (11) , 814-817
LIMIT Trial: Lidocaine With Intramuscular Injection of Benzathine Penicillin G for Treponema pallidum Treatment
Background: Studies have shown that intramuscular benzathine penicillin G (BPG) or bicillin injections cause severe pain in many patients, which may reduce adherence. Local anesthetics mixed with BPG may reduce injection pain without affecting drug effectiveness. The objective of this study was to examine if there is any benefit of adding 0.5 mL 1% lidocaine to prepackaged BPG, with respect to pain, compared with standard of care, in the treatment of Treponema pallidum infections, both 10 min and 24 h after injection. Methods: This study is a double-blinded randomized placebo-controlled trial of the effect on pain of the addition of 0.5 mL 1% lidocaine solution to a prepackaged BPG injection, compared with the addition of 0.5 mL normal saline solution, in adults being treated for syphilis ( T. pallidum ) infections, within the Infectious Diseases Clinic at Washington University in St. Louis, MO. Results: Preliminary analysis included 15 participants. A Wilcoxon signed-rank test indicated a statistically significant reduction in pain 10 min after lidocaine injection compared with the saline injection ( z = −2.65, P = 0.008). The mean pain score following administration, after 10 min, of the lidocaine solution was 3, compared with 6.73 for the saline solution. Overall, 87% of participants reported at least a 2-point reduction in pain scores after 10 min with lidocaine relative to saline. However, no significant difference in pain scores was observed between the 2 solutions at the 24-h follow-up. Conclusion: This trial demonstrates that lidocaine can help reduce the pain associated with intramuscular injections of BPG.
- 15 May 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (4) , 596-600
Real-World Implementation Outcomes of Lenacapavir for HIV Preexposure Prophylaxis: Early Findings From a Multicenter United States Cohort
Lenacapavir preexposure prophylaxis (PrEP) implementation across 17 US sites ( ampa#thinsp;= 501) was characterized by delays in initiation driven by payer processes. Early nonpersistence was uncommon (3.6%) but exceeded clinical trial discontinuation rates and was strongly associated with abdominal injections and injection-site reactions requiring clinical contact, underscoring modifiable barriers to early persistence.
- 15 May 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (4) , 596-600
Real-World Implementation Outcomes of Lenacapavir for HIV Preexposure Prophylaxis: Early Findings From a Multicenter United States Cohort
Lenacapavir preexposure prophylaxis (PrEP) implementation across 17 US sites ( ampa#thinsp;= 501) was characterized by delays in initiation driven by payer processes. Early nonpersistence was uncommon (3.6%) but exceeded clinical trial discontinuation rates and was strongly associated with abdominal injections and injection-site reactions requiring clinical contact, underscoring modifiable barriers to early persistence.
- 3 July 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (4) , e243-e244
Silence = Death Is Real Now More Than Ever, but Words Aren’t Enough—Action Is Needed!
- 3 July 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (4) , e243-e244
Silence = Death Is Real Now More Than Ever, but Words Aren’t Enough—Action Is Needed!
- Open Access
- 8 May 2021
- Published by MDPI AG in Journal of Fungi
- Vol. 7 (5) , 369
Long-Term Mortality after Histoplasma Infection in People with HIV
Histoplasmosis is a common opportunistic infection in people with HIV (PWH); however, no study has looked at factors associated with the long-term mortality of histoplasmosis in PWH. We conducted a single-center retrospective study on the long-term mortality of PWH diagnosed with histoplasmosis between 2002 and 2017. Patients were categorized into three groups based on length of survival after diagnosis: early mortality (death < 90 days), late mortality (death ≥ 90 days), and long-term survivors. Patients diagnosed during or after 2008 were considered part of the modern antiretroviral therapy (ART) era. Insurance type (private vs. public) was a surrogate indicator of socioeconomic status. Out of 54 PWH infected with histoplasmosis, overall mortality was 37%; 14.8% early mortality and 22.2% late mortality. There was no statistically significant difference in survival based on the availability of modern ART (p = 0.60). Insurance status reached statistical significance with 38% of survivors having private insurance versus only 8% having private insurance in the late mortality group (p = 0.05). High mortality persists despite the advent of modern ART, implicating a contribution from social determinants of health, such as private insurance. Larger studies are needed to elucidate the role of these factors in the mortality of PWH.
- 8 May 2021
- Published by MDPI AG in Journal of Fungi
- Vol. 7 (5) , 369
Open AccessLong-Term Mortality after Histoplasma Infection in People with HIV
Histoplasmosis is a common opportunistic infection in people with HIV (PWH); however, no study has looked at factors associated with the long-term mortality of histoplasmosis in PWH. We conducted a single-center retrospective study on the long-term mortality of PWH diagnosed with histoplasmosis between 2002 and 2017. Patients were categorized into three groups based on length of survival after diagnosis: early mortality (death < 90 days), late mortality (death ≥ 90 days), and long-term survivors. Patients diagnosed during or after 2008 were considered part of the modern antiretroviral therapy (ART) era. Insurance type (private vs. public) was a surrogate indicator of socioeconomic status. Out of 54 PWH infected with histoplasmosis, overall mortality was 37%; 14.8% early mortality and 22.2% late mortality. There was no statistically significant difference in survival based on the availability of modern ART (p = 0.60). Insurance status reached statistical significance with 38% of survivors having private insurance versus only 8% having private insurance in the late mortality group (p = 0.05). High mortality persists despite the advent of modern ART, implicating a contribution from social determinants of health, such as private insurance. Larger studies are needed to elucidate the role of these factors in the mortality of PWH.